FDG PET imaging in cystic fibrosis

Seminars in Nuclear Medicine

Volumn 43, Issue 6, 2013, Pages 412-419

  Chen, Delphine L ^a   Atkinson, Jeffrey J ^a   Ferkol, Thomas W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ACUTE LUNG INJURY; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG UPTAKE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; NEUTROPHIL COUNT; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; SPIROMETRY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG DISCOVERY; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; POSITRON-EMISSION TOMOGRAPHY;

EID: 84885131969     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2013.06.002     Document Type: Article

References (59)

1. A. Elizur, C.L. Cannon, and T.W. Ferkol Airway inflammation in cystic fibrosis Chest 133 2008 489 495
2. H. Matsui, B.R. Grubb, and R. Tarran Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease Cell 95 1998 1005 1015
3. R. Tarran, B. Button, and M. Picher Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections J Biol Chem 280 2005 35751 35759
4. M.R. Knowles, and R.C. Boucher Mucus clearance as a primary innate defense mechanism for mammalian airways J Clin Invest 109 2002 571 577
5. J.J. Smith, S.M. Travis, and E.P. Greenberg Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid Cell 85 1996 229 236
6. P.K. Singh, B.F. Tack, and P.B. McCray Jr. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid Am J Physiol Lung Cell Mol Physiol 279 2000 L799 L805
7. P.B. Davis, M. Drumm, and M.W. Konstan Cystic fibrosis Am J Respir Crit Care Med 154 1996 1229 1256 Official journal of the American Thoracic Society.
8. G.M. Nixon, D.S. Armstrong, and R. Carzino Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis J Pediatr 138 2001 699 704
9. S.D. Sagel, R.L. Gibson, and J. Emerson Impact of pseudomonas and staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis J Pediatr 154 2009 183 188
10. J.J. Lipuma The changing microbial epidemiology in cystic fibrosis Clin Microbiol Rev 23 2010 299 323
11. M.W. Konstan, K.A. Hilliard, and T.M. Norvell Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation Am J Respir Crit Care Med 150 1994 448 454
12. D.S. Armstrong, K. Grimwood, and J.B. Carlin Lower airway inflammation in infants and young children with cystic fibrosis Am J Respir Crit Care Med 156 1997 1197 1204
13. P.D. Sly, S. Brennan, and C. Gangell Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening Am J Respir Crit Care Med 180 2009 146 152
14. S.M. Stick, S. Brennan, and C. Murray Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening J Pediatr 155 2009 623 628 [e621]
15. L.S. Mott, J. Park, and C.P. Murray Progression of early structural lung disease in young children with cystic fibrosis assessed using CT Thorax 67 2012 509 516
16. K.J. Thorne, R.C. Oliver, and A.J. Barrett Lysis and killing of bacteria by lysosomal proteinases Infect Immun 14 1976 555 563
17. S.D. Sagel, B.D. Wagner, and M.M. Anthony Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis Am J Respir Crit Care Med 186 2012 857 865
18. A.P. Watt, J. Courtney, and J. Moore Neutrophil cell death, activation and bacterial infection in cystic fibrosis Thorax 60 2005 659 664
19. A. Gaggar, Y. Li, and N. Weathington Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients Am J Physiol Lung Cell Mol Physiol 293 2007 L96 L104
20. M.W. Konstan Ibuprofen therapy for cystic fibrosis lung disease: Revisited Curr Opin Pulm Med 14 2008 567 573
21. M.W. Konstan, P.J. Byard, and C.L. Hoppel Effect of high-dose ibuprofen in patients with cystic fibrosis N Engl J Med 332 1995 848 854
22. L. Saiman, B.C. Marshall, and N. Mayer-Hamblett Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial J Am Med Assoc 290 2003 1749 1756
23. J. Wolter, S. Seeney, and S. Bell Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial Thorax 57 2002 212 216
24. A. Equi, I.M. Balfour-Lynn, and A. Bush Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial Lancet 360 2002 978 984
25. S.D. Sagel, J.F. Chmiel, and M.W. Konstan Sputum biomarkers of inflammation in cystic fibrosis lung disease Proc Am Thorac Soc 4 2007 406 417
26. L.R. Hoffman, and B.W. Ramsey Cystic fibrosis therapeutics: The road ahead Chest 143 2013 207 213
27. C.P. Adams, and V.V. Brantner Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25 2006 420 428
28. F.J. Martinez, J.F. Donohue, and S.I. Rennard The future of chronic obstructive pulmonary disease treatment - Difficulties of and barriers to drug development Lancet 378 2011 1027 1037
29. R. Chakrabarti, C. Jung, and T. Lee Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin J Immunol 152 1994 2660 2668
30. S. Yamada, K. Kubota, and R. Kubota High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue J Nucl Med 36 1995 1301 1306
31. 18F- fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin PloS One 8 2013 e58917
32. C. Nanni, L. Boriani, and C. Salvadori FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis Eur J Nucl Med Mol Imaging 39 2012 1538 1544
33. D. Tezuka, G. Haraguchi, and T. Ishihara Role of FDG PET-CT in takayasu arteritis: Sensitive detection of recurrences JACC Cardiovasc Imaging 5 2012 422 429
34. A. Haroon, A. Zumla, and J. Bomanji Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders Clin Infect Dis 54 2012 1333 1341
35. S. Basu, T. Chryssikos, and S. Moghadam-Kia Positron emission tomography as a diagnostic tool in infection: Present role and future possibilities Semin Nucl Med 39 2009 36 51
36. C.P. Bleeker-Rovers, J.W. van der Meer, and W.J. Oyen Fever of unknown origin Semin Nucl Med 39 2009 81 87
37. H. Jones, S. Sriskandan, and A. Peters Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis Eur Respir J 10 1997 795 803
38. 18F]-fluoro-2-deoxy-D-glucose PET/CT study Crit Care Med 37 2009 2216 2222
39. R.S. Rodrigues, P.R. Miller, and F.A. Bozza FDG-PET in patients at risk for acute respiratory distress syndrome: A preliminary report Intensive Care Med 34 2008 2273 2278
40. H.A. Jones, P.S. Marino, and B.H. Shakur In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma Eur Respir J 21 2003 567 573
41. D.R. Subramanian, L. Jenkins, and R. Edgar Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography Am J Respir Crit Care Med 186 2012 1125 1132
42. 18F-fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: Implications for future clinical trials Eur J Nucl Med Mol Imaging 39 2012 521 528
43. 18F-FDG PET/CT J Nucl Med 50 2009 538 545
44. 18F] fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation Am J Respir Crit Care Med 180 2009 533 539
45. D.L. Chen, D.B. Rosenbluth, and M.A. Mintun FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin J Appl Physiol 100 2006 1602 1609
46. 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma J Nucl Med 52 2011 1713 1720
47. 18F]-fluorodeoxyglucose and positron emission tomography Lancet 347 1996 937 940
48. D.L. Chen, T.W. Ferkol, and M.A. Mintun Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography Am J Respir Crit Care Med 173 2006 1363 1369 Official journal of the American Thoracic Society.
49. C.S. Patlak, R.G. Blasberg, and J.D. Fenstermacher Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1983 1 7
50. D.B. Rosenbluth, K. Wilson, and T. Ferkol Lung function decline in cystic fibrosis patients and timing for lung transplantation referral Chest 126 2004 412 419
51. 18fluorodeoxyglucose in the cystic fibrosis lung: A measure of lung inflammation? Eur Respir J 21 2003 848 854
52. M.B. Dolovich, and D.P. Schuster Positron emission tomography and computed tomography versus positron emission tomography computed tomography: Tools for imaging the lung Proc Am Thorac Soc 4 2007 328 333
53. 18F- fluorodeoxyglucose-pet/ct imaging of lungs in patients with cystic fibrosis Chest 136 2009 1220 1228
54. 18F-FDG uptake with pet during experimental acute lung injury J Nucl Med 45 2004 1583 1590
55. R. Amin, M. Charron, and L. Grinblat Cystic fibrosis: Detecting changes in airway inflammation with FDG PET/CT Radiology 264 2012 868 875
56. A.S. Brody, M.R. Kosorok, and Z. Li Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis J Thorac Imaging 21 2006 14 21
57. F.H. Fahey, S.T. Treves, and S.J. Adelstein Minimizing and communicating radiation risk in pediatric nuclear medicine J Nucl Med 52 2011 1240 1251
58. O.J. O'Connor, M. Vandeleur, and A.M. McGarrigle Development of low-dose protocols for thin-section ct assessment of cystic fibrosis in pediatric patients Radiology 257 2010 820 829
59. A. Faro, P. Michelson, and T. Ferkol Pulmonary disease in cystic fibrosis R.W. Wilmott, T.F. Boat, A. Bush, V. Chernick, R.R. Deterding, F. Ratjen, Disorders of the Respiratory Tract in Children ed 8 2012 Elsevier Health Sciences Philadelphia, PA 770 780